Health Care • Industrial Specialties
$2.35 ▲ +0.49
(+26.34%)
MKT CAP: $294.2M • VOL: 3.69M
52W L $2 52W H $8
ROARABLE / RQD
D- • 36/100
PIOTROSKI
4 / 9
ZJYL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $20.7M | $23.5M | $19.8M |
| YoY Revenue Growth % | -12.0% | +18.6% | — |
| Gross Profit | $6.0M | $9.5M | — |
| Gross Margin % | 29.2% | 40.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $608.2K | $3.6M | $2.9M |
| Operating Margin % | 2.9% | 15.5% | 14.5% |
| Net Income (GAAP) | $1.2M | $3.7M | $2.9M |
| EBITDA (Normalized) | $5.9M | $3.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $2.9M | -$1.2M | $3.1M |
| Capital Expenditures (CapEx) | $6.6M | $144.9K | — |
| Free Cash Flow (FCF) | -$3.7M | -$1.4M | $3.1M |
| FCF Margin % | -18.0% | -5.8% | 15.7% |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | — | — | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZJYL.